ESTROGEN, INCONTINENCE, PROSTATE CANCER GENE
A single variation on one gene may increase a man’s risk of prostate cancer by 50%. Researchers at Mount Sinai School of Medicine published their findings in the journal Cancer Research. The gene called klf6 normally suppresses the growth of prostate cancer. If abnormal, it allows the growth. The abnormal version of the gene was seen much more frequently in prostate cancer patients with a family history of the disease compared to those without prostate cancer. Overall, carrying the abnormal version of the gene causes an approximately 50% increased risk for developing prostate cancer.
The researchers say the finding has profound implications.
“What we’re very excited about is that now we’re starting to think about a diagnostic based on a precancerous change found in blood, but also potentially a real target-able molecule to try controlling growth,” explains Dr. John Martignetti, assistant professor of human genetics at Mount Sinai School of Medicine.
It has since been discovered that klf6 defects are implicated in a number of other human cancers, including colorectal, lung and liver.
What has been long considered a treatment for urinary incontinence, especially for post menopausal women, may in fact cause the problem instead. New research in the latest journal of the American Medical Association shows that estrogen alone or with progestin—actually increases the chance of female incontinence.
Researchers at Wayne State University School of Medicine used data from a large study called the Women’s Health Initiative. The study was designed to evaluate the effects of hormone replacement using estrogen and progestin or estrogen alone in preventing coronary heart disease and hip fractures in postmenopausal women. Both trials ended prematurely because more harm than benefit was seen.
The researchers found that post-menopausal hormone therapy as much as doubled the risk of getting urinary incontinence. Among women who already had the problem, the medications worsened the problem.
The authors argue that doctors should not longer prescribe long term estrogen for treatment of female incontinence in postmenopausal women.
There are experts who disagree with the findings, saying how the study was performed was inaccurate.
“I have a problem with this study in so far as a questionnaire a year down the line being the main measurement of whether these women developed incontinence as opposed to an objective test such as leakage with coughing or a formal urodynamics test, which is the most accurate way of looking into this problem,” says Dr. Lawrence Lind, chief of urogynecology at North Shore Long Island Jewish Health System.
It is agreed, though, that half of women with urinary incontinence fail to even discuss the problem with their doctor, and they should absolutely do so to look at all the possible treatment options for female incontinence.
Purchase Acceletrim Today
Acceletrim Weight Loss
Acceletrim Weight Loss
Acceletrim Weight Loss
,
Call 888-245-5530
If you ever felt it's impossible to loose weight, you're not alone. Let's face it many struggle to get to their ideal weight. With Acceletrim you don't have to battle by yourself. Acceletrim helps you loose weight naturally by suppressing your cravings and speeding up your metabolism. Look and feel your best with Acceletrim Weight Loss.